| Literature DB >> 35102430 |
Alessandro Esposito1, Marco Ramera1, Luca Casetti1, Matteo De Pastena1, Martina Fontana1, Isabella Frigerio2, Alessandro Giardino2, Roberto Girelli2, Luca Landoni1, Giuseppe Malleo1, Giovanni Marchegiani1, Salvatore Paiella1, Antonio Pea1, Paolo Regi2, Filippo Scopelliti2, Massimiliano Tuveri1, Claudio Bassi3,4, Roberto Salvia1, Giovanni Butturini2.
Abstract
BACKGROUND: This study aimed to discuss and report the trend, outcomes, and learning curve effect after minimally invasive distal pancreatectomy (MIDP) at two high-volume centres.Entities:
Keywords: Distal pancreatectomy; Laparoscopic surgery; Learning curve; Pancreatic ductal adenocarcinoma; Robotic surgery; Trocar site recurrence
Mesh:
Year: 2022 PMID: 35102430 PMCID: PMC9402493 DOI: 10.1007/s00464-021-08997-8
Source DB: PubMed Journal: Surg Endosc ISSN: 0930-2794 Impact factor: 3.453
Fig. 1A Involvement of main surgeons over the years. B Number of laparoscopic and robotic distal pancreatectomy per institution and percentage of MIDP on the total of distal pancreatectomies per year, 1999 to 2018
Demographics and pathologic variables
| Overall | Early phase | Recent phase | ||
|---|---|---|---|---|
| 401 | 201 | 200 | ||
| Years included | 1999–2018 | 1999–2014 | 2015–2018 | |
| Demographics | ||||
| Sex (Female) | 277 (69%) | 151 (75%) | 126 (63%) | |
| Age, yr | 52 (40–64) | 49 (38–62) | 55 (43–65) | |
| BMI, kg/m2 | 24 (21–27) | 23.3 (20.3–26.9) | 24.5 (21.6–27.5) | 0.072† |
| BMI ≥ 25 kg/m2 | 155 (42%) | 71 (38%) | 84 (46%) | 0.093* |
| Previous abdominal surgery | 88 (22%) | 20 (10%) | 68 (34%) | |
| ASA | ||||
| 1 | 65 (16%) | 36 (18%) | 29 (14%) | |
| 2 | 313 (78%) | 159 (79%) | 154 (77%) | |
| 3 | 23 (6%) | 6 (3%) | 17 (9%) | |
| Pathologic variables | ||||
| Cystic lesion | 152 (38%) | 95 (47%) | 57 (28%) | |
| pNET | 139 (35%) | 64 (32%) | 75 (37%) | |
| PDAC | 45 (11%) | 15 (7%) | 30 (15%) | |
| SPT | 42 (10%) | 21 (11%) | 21 (11%) | |
| Others | 23 (6%) | 6 (3%) | 17 (9%) | |
| Size, mm | 30 (20–41) | 30 (20–45) | 30 (20–40) | 0.244† |
| Harvested lymph nodes | 13 (6–21) | 10 (4–19) | 16 (8–24) | < |
Bold values indicate statistical significance (p < 0.05)
All values presented as n (%), or median (IQR)
BMI Body Mass Index, ASA American Society of Anesthesiologists, pNET pancreatic Neuroendocrine Tumor, PDAC Pancreatic Ductal Adenocarcinoma, SPT Solid Pseudopapillary Tumor
*Pearson Chi-square
†Mann–Whitney U Test
Intraoperative and postoperative outcomes
| Overall | Early phase | Recent phase | ||
|---|---|---|---|---|
| 401 | 201 | 200 | ||
| Years included | 1999–2018 | 1999–2014 | 2015–2018 | |
| Intraoperative outcomes | ||||
| Conversion to open | 31 (8%) | 20 (10%) | 11 (6%) | 0.095 |
Approach: Lap | 300 (75%) | 160 (80%) | 140 (70%) | |
| Rob | 101 (25%) | 41 (20%) | 60 (30%) | |
| Spleen-preserving | 110 (27%) | 65 (32%) | 45 (23%) | |
| Kimura | 92 (84%) | 54 (83%) | 38 (84%) | 0.849* |
| Warshaw | 18 (16%) | 11 (17%) | 7 (16%) | |
| Operative time | 235 (190–294) | 210 (170–255) | 265 (216–327) | |
| Transection technique | ||||
| Stapler | 242 (60%) | 109 (54%) | 133 (67%) | |
| Ultrasonic dissector | 144 (36%) | 78 (39%) | 66 (33%) | |
| Others | 15 (4%) | 14 (7%) | 1 (1%) | |
| IO Blood transfusion | 11 (3%) | 9 (5%) | 2 (1%) | |
| Postoperative outcomes | ||||
| Overall morbidity | 194 (48%) | 96 (47.8%) | 98 (49%) | 0.804* |
| Surgical morbidity | 156 (39%) | 71 (35.3%) | 85 (42.5%) | 0.141* |
| Clavien-Dindo ≥ 3 | 45 (11%) | 22 (10.9%) | 23 (11.5%) | 0.860* |
| POPF | 89 (22%) | 40 (20%) | 49 (25%) | 0.268* |
| Grade B | 78 (19%) | 32 (16%) | 46 (23%) | 0.078* |
| Grade C | 11 (3%) | 8 (4%) | 3 (2%) | |
| Biochemical leak | 96 (24%) | 43 (21%) | 53 (27%) | 0.231* |
| PPH | 38 (10%) | 20 (10%) | 18 (9%) | 0.745* |
| Blood transfusion | 42 (11%) | 19 (9%) | 23 (12%) | 0.755* |
| Intra-abdominal collection | 98 (24%) | 41 (20%) | 57 (29%) | 0.059* |
| Reoperation | 36 (9%) | 21 (10%) | 15 (8%) | 0.302* |
| Wound infection | 3 (1%) | 1 (0.5%) | 2 (1%) | 0.623¶ |
| Medical morbidity | 109 (27%) | 58 (29%) | 51 (26%) | 0.450* |
| LoS | 8 (6–11) | 7 (6–10) | 8 (7–12) | |
| Readmission (90-d) | 42 (10%) | 18 (9%) | 24 (12%) | 0.319* |
| Mortality (90-d) | 0 | 0 | 0 | – |
Bold values indicate statistical significance (p < 0.05)
All values presented as n (%), or median (IQR)
MI Minimally Invasive, Lap Laparoscopy, Rob Robotic Surgery, IO intraoperative, POPF Post-Operative Pancreatic Fistula, PPH Post-Pancreatectomy Hemorrhage, LoS Length of Stay
*Pearson Chi-square
†Mann–Whitney U Test
¶ Fisher’s Exact Test
17 LDP – 10 RDP
| First 17 LDP | Subsequent LDP | First 10 RDP | Subsequent RDP | |||
|---|---|---|---|---|---|---|
| 138 | 162 | 45 | 56 | |||
| Demographics | ||||||
| Sex (Female) | 92 (67%) | 113 (70%) | 0.567* | 11 (24%) | 18 (32.1%) | 0.395* |
| Age ≥ 65y | 30 (22%) | 33 (20%) | 0.772* | 10 (22%) | 16 (28.6%) | 0.468* |
| BMI ≥ 25 kg/m2 | 48 (38%) | 66 (44%) | 0.274* | 17 (37%) | 24 (43%) | 0.525* |
| Prior abdominal surgery | 21 (15%) | 40 (25%) | 0.114* | 12 (27%) | 15 (27%) | 0.902* |
| ASA ≥ 3 | 13 (9%) | 5 (3%) | 4 (9%) | 1 (2%) | 0.169¶ | |
| Intraoperative outcomes | ||||||
| Conversion to open | 15 (11%) | 10 (6%) | 0.142* | 4 (9%) | 2 (4%) | 0.403¶ |
| Spleen-preserving | 39 (28%) | 40 (25%) | 0.484* | 13 (29%) | 18 (32%) | 0.725* |
| Kimura | 31 (80%) | 33 (83%) | 0.733* | 11 (85%) | 17 (94%) | 0.849* |
| Warshaw | 8 (20%) | 7 (17%) | 2 (15%) | 1 (6%) | ||
| Operative time | 240 (200–296) | 210 (163–255) | 274 (237–344) | 280 (230–337) | 0.730† | |
| Transection technique | ||||||
| Stapler | 96 (70%) | 107 (66%) | 0.106* | 14 (31%) | 25 (44%) | 0.381* |
| Ultrasonic dissector | 33 (24%) | 51 (32%) | 30 (67%) | 30 (54%) | ||
| Others | 9 (6%) | 4 (2%) | 1 (2%) | 1 (2%) | ||
| IO Blood transfusion | 3 (2%) | 4 (2%) | 0.999¶ | 4 (9%) | 0 | |
| Postoperative outcomes | ||||||
| Overall morbidity | 79 (57%) | 65 (40%) | 23 (51%) | 27 (48%) | 0.772* | |
| Surgical morbidity | 61 (44%) | 50 (31%) | 22 (49%) | 23 (41%) | 0.432* | |
| Clavien-Dindo < 3 | 61 (44%) | 51(31%) | 16 (36%) | 21 (38%) | 0.840* | |
| Clavien-Dindo ≥ 3 | 18 (13%) | 14 (9%) | 0.218* | 7 (16%) | 6 (11%) | 0.470* |
| POPF | 31 (23%) | 33 (20%) | 0.659* | 12 (27%) | 13 (23%) | 0.689* |
| Grade B | 26 (19%) | 29 (18%) | 0.815* | 11 (25%) | 12 (21%) | 0.922* |
| Grade C | 5 (3%) | 4 (2%) | 1 (2%) | 1 (2%) | ||
| PPH | 17 (12%) | 14 (9%) | 0.297* | 4 (9%) | 3 (5%) | 0.697¶ |
| Blood transfusion | 14 (10%) | 15 (9%) | 0.739* | 7 (16%) | 6 (11%) | 0.470* |
| Intra-abdominal collection | 39 (28%) | 28 (17%) | 16 (36%) | 15 (27%) | 0.342* | |
| Reoperation | 15 (11%) | 12 (7%) | 0.296* | 5 (11%) | 4 (7%) | 0.507¶ |
| LoS | 8 (7–11) | 7 (6–10) | 6 (8–12) | 6 (8–13) | 0.786† | |
| Readmission (90-d) | 12 (9%) | 15 (9%) | 0.865* | 9 (20%) | 6 (11%) | 0.192* |
| 90-d mortality | 0 | 0 | – | 0 | 0 | – |
| Pathologic variables | ||||||
| PDAC | 20 (14%) | 17 (10%) | 0.294* | 0 | 8 (14%) | |
| Harvested lymph nodes | 14 (6–22) | 16 (7–21) | 0.492† | 8 (3–17) | 10 (3–19) | 0.625† |
Bold values indicate statistical significance (p < 0.05)
All values presented as n (%), or median (IQR)
* Pearson Chi-square
† Mann–Whitney U Test
¶ Fisher’s Exact Test
LDP Laparoscopic Distal Pancreatectomy, RDP Robotic Distal Pancreatectomy, BMI Body Mass Index, ASA American Society of Anesthesiologists, IO intraoperative, POPF Post-Operative Pancreatic Fistula, PPH Post-Pancreatectomy Hemorrhage, LoS Length of Stay, PDAC Pancreatic Ductal Adenocarcinoma
Distal pancreatectomy with splenectomy vs Spleen-preserving
| DP-S | SP-DP | |||
|---|---|---|---|---|
| 291 | 110 | |||
| Intraoperative outcomes | ||||
| MI approach: Lap | 221 (76%) | 79 (72%) | 0.396* | |
| Rob | 70 (24%) | 31 (28%) | ||
| Conversion to open | 31 (11%) | 0 | ||
| Operative time | 250 (210–304) | 195 (153–240) | ||
| IO blood transfusion | 9 (3%) | 2 (2%) | 0.735¶ | |
| Postoperative outcomes | ||||
| Overall morbidity | 150 (52%) | 44 (40%) | ||
| Surgical morbidity | 120 (41%) | 36 (32.7%) | 0.119* | |
| Clavien-Dindo ≥ 3 | 33 (11%) | 12 (11%) | 0.903* | |
| POPF | 76 (26%) | 13 (12%) | ||
| Grade B | 67 (23%) | 11 (10%) | ||
| Grade C | 9 (3%) | 2 (2%) | ||
| Biochemical leak | 68 (23%) | 28 (25%) | 0.662* | |
| PPH | 28 (10%) | 10 (9%) | 0.871* | |
| Blood transfusion | 37 (13%) | 5 (5%) | ||
| Intra-abdominal collection | 73 (25%) | 25 (23%) | 0.624* | |
| Reoperation | 26 (9%) | 10 (9%) | 0.961* | |
| LoS | 8 (6–11) | 7 (6–9) | ||
| Readmission (90-d) | 28 (10%) | 14 (13%) | 0.365* | |
| 90-d mortality | 0 | 0 | – | |
Bold values indicate statistical significance (p < 0.05)
All values presented as n (%), or median (IQR)
DP-S Distal Pancreatectomy with Splenectomy, SP-DP Spleen-preserving Distal Pancreatectomy, MI Minimally Invasive, Lap Laparoscopy, Rob Robotic Surgery, IO intraoperative, POPF Post-Operative Pancreatic Fistula, PPH Post-Pancreatectomy Hemorrhage, LoS Length of Stay
*Pearson Chi-square
†Mann–Whitney U Test
¶Fisher’s Exact Test
PDAC: pathological variables and follow-up
| N (%) or Median (IQR) | |
|---|---|
| 45 | |
| Pathologic variables | |
| Dimension, mm | 30 (20–35) |
| R0 | 42 (93%) |
| Perineural invasion | 41 (91%) |
| N1 | 29 (64%) |
| Follow-up | |
| Median follow up (IQR), months | 31 (25.5–53) |
| 1y survival | 96% |
| 3y survival | 71% |
| Recurrence | 32 (71%) |
| Trocar-site | 3 (7%) + 1 thoracic trocar |
Fig. 2Overall survival in patients undergoing minimally invasive distal pancreatectomy for PDAC